How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy

por Tang, Ya-Chu, Chuang, Yung-Jen, Chang, Hsin-Huei, Juang, Shin-Hun, Yen, Gow-Chin, Chang, Jang-Yang, Kuo, Ching-Chuan
Publicado 2023

A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

por Tang, Ya-Chu, Chang, Hsin-Huei, Chen, Huang-Hui, Yao, Jau-Ying, Chen, Yu-Tsen, Chuang, Yung-Jen, Chang, Jang-Yang, Kuo, Ching-Chuan
Publicado 2021

LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation

por Lee, Chia-Huei, Pan, Kao-Lu, Tang, Ya-Chu, Tsai, Ming-Hsien, Cheng, Ann-Joy, Shen, Mei-Ya, Cheng, Ying-Min, Huang, Tze-Ta, Lin, Pinpin
Publicado 2015

c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation

por Tang, Ya-Chu, Hsiao, Jenn-Ren, Jiang, Shih-Sheng, Chang, Jang-Yang, Chu, Pei-Yi, Liu, Ko-Jiunn, Fang, Hsun-Lang, Lin, Li-Mei, Chen, Huang-Hui, Huang, Yen-Wen, Chen, Yu-Tsen, Tsai, Fang-Yu, Lin, Su-Fang, Chuang, Yung-Jen, Kuo, Ching-Chuan
Publicado 2021